Sort   by:  
 Page size 
UnknownDurvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Not available
S-EPMC12282661 | biostudies-literature
UnknownBurden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535840 | biostudies-literature
UnknownPrevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study.
Not available
S-EPMC7880913 | biostudies-literature
Sort   by:  
 Page size